Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.44 |
| ▸ | WNT1 | P04628 | 4/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633364 | 1.00 | AURKA (0.44) | AURKAAURKBNUDT1WNT1DYRK1A | |
| SCHEMBL26686261 | 0.85 | DYRK1A (0.56) | AURKAAURKBNUDT1WNT1DYRK1A | |
| SCHEMBL30633374 | 0.85 | DYRK1A (0.56) | AURKAAURKBNUDT1WNT1DYRK1A | |
| SCHEMBL26686587 | 0.81 | KDM4E (0.55) | WNT1DYRK1AKDM4EHSD17B10RHEB | |
| SCHEMBL30633400 | 0.81 | KDM4E (0.55) | WNT1DYRK1AKDM4EHSD17B10RHEB | |
| SCHEMBL26686734 | 0.74 | CCNK (0.44) | AURKAAURKB | |
| SCHEMBL31240454 | 0.74 | DYRK1A (0.54) | WNT1DYRK1APARP1APP | |
| SCHEMBL31240468 | 0.72 | CCNK (0.52) | NUDT1 | |
| SCHEMBL26686752 | 0.72 | CCNK (0.52) | NUDT1 | |
| SCHEMBL31240736 | 0.72 | NUDT1 (0.49) | NUDT1WNT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | AURKA 269/4885AURKB 161/4885NUDT1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.